Nabil M. Mansour, Shawn S. Groth, Sharmila Anandasabapathy
文献索引:10.1146/annurev-med-050715-104218
全文:HTML全文
Esophageal adenocarcinoma (EAC) is a growing problem with a rapidly rising incidence. Risk factors include gastroesophageal reflux disease, central obesity, and smoking. The prognosis of EAC remains poor because it is usually diagnosed late, and many efforts have been made to improve prevention, early detection, and treatment. Acid suppression, nonsteroidal antiinflammatory drugs (NSAIDs), and statins may play a role in chemoprevention. Screening for Barrett's esophagus (BE), the only known precursor lesion of EAC, is indicated for individuals with increased risk. Endoscopic surveillance of patients with BE likely improves overall outcomes. Endoscopic ablation and resection is highly effective for treating dysplastic BE and early EAC, whereas esophagectomy is indicated for patients with locally advanced disease. This review covers epidemiology, staging, screening, and prevention of EAC as well as endoscopic and surgical management.
Gene Editing: A New Tool for Viral Disease
2017-01-18 [10.1146/annurev-med-051215-031129] |
The Type I Interferonopathies
2017-01-18 [10.1146/annurev-med-050715-104506] |
Management of Rectal Cancer Without Radical Resection
2017-01-18 [10.1146/annurev-med-062915-021419] |
The End of Nihilism: Systemic Therapy of Advanced Non–Small ...
2017-01-18 [10.1146/annurev-med-042915-102442] |
CAR T Cell Therapy for Solid Tumors
2017-01-18 [10.1146/annurev-med-062315-120245] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved